SARS-CoV-2 mAb cocktail effective against all known variants of virus
63
A monoclonal antibody (mAb) cocktail, that targets sites on the Spike protein other than the E484K residue, can neutralise SARS-CoV-2.
A monoclonal antibody (mAb) cocktail to neutralise the COVID-19 virus developed at Vanderbilt University Medical Center (VUMC), US, is effective against all known strains, or variants, of the virus, according to researchers. The study was led by scientists at Washington University School of Medicine in St Louis, US.
In cell culture studies, the researchers determined the ability of mAbs, as well as antibodies isolated from the convalescent plasma of previously infected people, to neutralise highly transmissible variants of the SARS-CoV-2 virus that have arisen in the UK, South Africa, Brazil and elsewhere.
New research conducted at Washington University School of Medicine in St. Louis has indicated that a trio of new and fast-spreading variants of the virus that
Updated Mar 08, 2021 | 13:30 IST
Bharat Biotech has begun the first phase of clinical trials of the intranasal Covid-19 vaccine which is being developed in collaboration with the Washington University School of Medicine. Hyderabad: Phase 1 trials of Bharat Biotech’s intranasal Covid-19 vaccine begins. | Photo Credit: AP
In what comes as good news for India in the fight against the novel coronavirus, Bharat Biotech has started the phase 1 human clinical trials of intranasal Covid-19 vaccine. The vaccine codenamed BBV154 will undergo trials at various hospitals in Hyderabad, Nagpur, Patna, and Chennai.
The trials will be conducted at selected sites in these cities. Bharat Biotech is developing the intranasal Covid-19 vaccine in collaboration with the Washington University School of Medicine. 175 healthy volunteers between the age of 45-60 will be administered with the doses as part of the clinical trials.
The U.S. new cases 7-day rolling average are 10.9 % LOWER than the 7-day rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 13.8 %
LOWER than the rolling average one week ago. U.S. deaths due to coronavirus are now 12.0 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 45,864
U.S. Coronavirus hospitalizations are at 40,212
U.S. Coronavirus deaths are at 669
U.S. Coronavirus immunizations have been administered to 27.0 % of the population
The 7-day rolling average rate of growth of the pandemic shows new cases improved, hospitalizations little changed, and deaths improved. The best monitoring tool, hospitalizations, has been showing continuous improvement.